Role of Jak3 in Anaplastic Large Cell Lymphoma

Jak3 在间变性大细胞淋巴瘤中的作用

• 批准号: 7468066
• 负责人: HESHAM M AMIN
• 金额: $ 13.61万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7468066
• 关键词: 2p23; Affect; Agar; Age; Agreement; Apoptosis; Appendix; Applications Grants; Biology; Blood; Cancer Biology; Cancer Center; Cell Cycle Arrest; Cell Line; Cell Survival; Cells; Child; Chromosomal translocation; Chromosome abnormality; Chromosomes; Clinic; Data; Development; Disease; Doctor of Medicine; Dominant-Negative Mutation; Down-Regulation; Elements; Enzymes; Equilibrium; Foundations; Gene Targeting; Genes; Goals; Growth; Human; Immunophenotyping; Interleukin 2 Receptor Gamma; Interleukin-15; Interleukin-2; Interleukin-7; Interleukin-9; Interleukins; Janus kinase 3; Ki-1 Large-Cell Lymphoma; Knowledge; Large-Cell Lymphomas; Lymphoma; Malignant Neoplasms; Manuscripts; Mediating; Mentors; Mission; Non-Hodgkin' s Lymphoma; Null Lymphocytes; Numbers; Oncogenes; Oncogenic; Pathogenesis; Patients; Phosphoric Monoester Hydrolases; Phosphotransferases; Physicians; Physiological; Play; Primary Neoplasm; Protein Tyrosine Kinase; Public Health; Publications; Relapse; Research; Research Personnel; Role; Sampling; Scientist; Signal Transduction; Solid; Staining method; Stains; Survival Rate; Testing; Therapeutic; Transfection; Translating; Treatment Protocols; Tumor Cell Line; Tyrosine Kinase Domain; anaplastic lymphoma kinase; base; cancer type; career; clinically significant; inhibitor/antagonist; insight; interleukin 9 receptor; neutralizing antibody; novel therapeutics; nucleophosmin; programs; promoter; receptor; research study; skills; src Homology Region 2 Domain; t(2; 5)(p23; q35); therapeutic target; tumor; tumorigenesis; young adult

DESCRIPTION (provided by applicant): Project Summary: The overall goal of this grant application is to acquire the opportunity to develop the knowledge and skills to become an independent physician-scientist who effectively translates bench studies to the clinic. Establishing a solid research foundation is one of the key elements with this approach. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is an aggressive malignant lymphoma of T/null-cell immunophenotype. It frequently affects children and young adults, and an estimated 40-50% of the patients fail current therapeutics. Janus kinase 3 (Jak3) is a protein tyrosine kinase with biologic functions related to cell survival and tumorigenesis. Our preliminary studies showed that Jak3 is constitutively activated in ALK+ ALCL cell lines and that inhibition of Jak3 decreases cell viability due to apoptosis and cell cycle arrest. Our preliminary studies also showed that Jak3 and ALK are physically associated and that inhibition of Jak3 decreases ALK kinase activity. Further, we found that ALK+ ALCL patients with tumors expressing activated Jak3 tend to have a lower survival rate than in ALK+ ALCL patients with tumors lacking the expression of activated Jak3. In addition, we demonstrated that IL-9 contributes to Jak3 activation by showing that IL-9 receptor-( and IL-9 are expressed in ALK+ ALCL cell lines and in most human primary tumors. Moreover, an anti-IL-9 neutralizing antibody decreased levels of activated Jak3 in and soft agar colony formation of ALK+ ALCL cells. Our preliminary studies also demonstrated that a major physiologic inhibitor of Jak3, SHP1, is absent or gene methylated in ALK+ ALCL cell lines and in most human tumors. Transfection of SHP1 into ALK+ ALCL cells induced downregulation of activated Jak3 levels. On the basis of these results, we hypothesize that constitutive activation of Jak3 by multilevel dysregulation plays an important role in the pathogenesis of ALK+ ALCL. The specific aims of this proposal are to 1) define the pathogenetic role of Jak3 in ALK+ ALCL and 2) establish the biologic and clinical significance of Jak3 activation in tumors from ALK+ ALCL patients. The global aim of the proposed studies is to identify Jak3 as a potential therapeutic target in ALK+ ALCL patients; this aim is in complete agreement with the mission of M.D. Anderson Cancer Center of bringing novel therapeutics to the clinic. The balanced program of mentored research and career development proposed in this application will provide the applicant with a solid foundation for a successful career as an independent investigator in cancer biology. Relevance to public health: ALK+ ALCL is an aggressive type of cancer that commonly affects children and young adults. Our preliminary results showed that the enzyme Jak3 plays an important role in the development and progression of ALK+ ALCL. The direct aim of the proposed studies is to validate Jak3 as a therapeutic target in patients afflicted with this dreadful disease.

描述（由申请人提供）：项目摘要：本补助金申请的总体目标是获得发展知识和技能的机会，成为一名独立的医生，科学家，有效地将实验室研究转化为临床。建立坚实的研究基础是这种方法的关键要素之一。间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤（ALK+ ALCL）是一种T/裸细胞免疫表型的侵袭性恶性淋巴瘤。它经常影响儿童和年轻人，估计有40-50%的患者在目前的治疗中失败。Janus激酶3（Jak 3）是一种蛋白酪氨酸激酶，具有与细胞存活和肿瘤发生相关的生物学功能。我们的初步研究表明，Jak 3在ALK+ ALCL细胞系中被组成性激活，抑制Jak 3会因细胞凋亡和细胞周期停滞而降低细胞活力。我们的初步研究还表明，Jak 3和ALK是物理相关的，抑制Jak 3会降低ALK激酶活性。此外，我们发现，肿瘤表达活化Jak 3的ALK+ ALCL患者的生存率往往低于肿瘤缺乏活化Jak 3表达的ALK+ ALCL患者。此外，我们通过显示IL-9受体和IL-9在ALK+ ALCL细胞系和大多数人原发性肿瘤中表达，证明了IL-9有助于Jak 3活化。此外，抗IL-9中和抗体降低了ALK+ ALCL细胞中活化Jak 3的水平和软琼脂集落形成。我们的初步研究还表明，在ALK+ ALCL细胞系和大多数人类肿瘤中，Jak 3的主要生理抑制剂SHP 1不存在或基因甲基化。将SHP 1转染到ALK+ ALCL细胞中可诱导活化的Jak 3水平下调。基于这些结果，我们假设多水平失调引起的Jak 3组成性激活在ALK+ ALCL的发病机制中发挥重要作用。本提案的具体目的是：1）确定Jak 3在ALK+ ALCL中的致病作用; 2）确定Jak 3激活在ALK+ ALCL患者肿瘤中的生物学和临床意义。拟定研究的总体目标是将Jak 3确定为ALK+ ALCL患者的潜在治疗靶点;该目标与M.D.的使命完全一致。安德森癌症中心将新的治疗方法带到临床。本申请中提出的指导研究和职业发展的平衡计划将为申请人作为癌症生物学独立研究者的成功职业生涯奠定坚实的基础。与公共卫生的相关性：ALK+ ALCL是一种侵袭性癌症，通常影响儿童和年轻人。我们的初步结果表明，酶Jak 3在ALK+ ALCL的发生和进展中起着重要作用。这些研究的直接目的是验证Jak 3作为这种可怕疾病患者的治疗靶点。

项目成果

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.

• DOI: 10.1111/j.1582-4934.2009.00795.x
• 发表时间: 2010-06
• 期刊: Journal of cellular and molecular medicine
• 影响因子: 5.3
• 作者: Shi P;Chandra J;Sun X;Gergely M;Cortes JE;Garcia-Manero G;Arlinghaus RB;Lai R;Amin HM
• 通讯作者: Amin HM